Document is current
Any future updates will be listed below
-
Authors
Mortada, Ahmed M. https://orcid.org/0009-0006-7364-9419
Darwesh, Alaa Y. https://orcid.org/0000-0002-9875-8818
Taha, Iman E. https://orcid.org/0009-0001-1969-1273
Anekalla, Thirupathi R. https://orcid.org/0009-0000-6671-1188
Mostafa, Nourhan https://orcid.org/0009-0004-6290-8599
Maniruzzaman, Mohammed https://orcid.org/0000-0002-3373-5586
- License Information
-
More Information
Article History
Received: 17 December 2025
Accepted: 3 February 2026
First Online: 17 March 2026
Consent for Publication
: All authors have reviewed the final version of the manuscript and approve its submission for publication in pharmaceutical research.
: AI technology WAS NOT employed in the creation of this manuscript, but used to check the writing and grammar.
: Ahmed Mortada (A.M.), Alaa Darwesh (A.D.) and Mohammed Maniruzzaman (M.M.) are co-inventors of related intellectual property (IP). M.M., an author of this manuscript, holds stock in, serves on a scientific advisory board for, or is a consultant for CoM3D Ltd. (Surrey, UK), DosePlus Therapeutics, Inc. (Princeton, NJ, USA), Septum Solutions LLC (Houston, TX, USA), and SmarGic Tech LLC (Oxford, MS, USA). The companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.
